Patents Examined by Brandon J. Fetterolf
  • Patent number: 11974969
    Abstract: The invention provides an artificially synthesized single sphingosine lipid and use of delivering a nucleic acid thereof.
    Type: Grant
    Filed: March 29, 2019
    Date of Patent: May 7, 2024
    Assignee: INSTITUTE OF BASIC MEDICAL SCIENCES CHINESE ACADEMY OF MEDICAL SCIENCES
    Inventors: Chengyu Jiang, Yuhao Qin, Xiaoyun Li, Cong Zhang
  • Patent number: 11931360
    Abstract: Compositions and methods for treatment of cancer according to aspects of the present disclosure comprise compounds comprising or consisting of: structural formula (I) or (II) disclosed herein, or a salt, isomer, or derivative thereof.
    Type: Grant
    Filed: June 23, 2022
    Date of Patent: March 19, 2024
    Assignee: Wayne State University
    Inventors: Isaac J. Powell, Navnath S. Gavande
  • Patent number: 11919879
    Abstract: Provided herein are compounds and compositions thereof for modulating S1P5. In some embodiments, the compounds and compositions are provided for treatment of neurological diseases.
    Type: Grant
    Filed: June 15, 2022
    Date of Patent: March 5, 2024
    Assignee: Celgene Corporation
    Inventors: Jeffrey M. Schkeryantz, Karin Worm, Rulin Ma, Patrick W. Papa
  • Patent number: 11912699
    Abstract: The present disclosure relates to bifunctional compounds, which find utility as modulators of tau protein. In particular, the present disclosure is directed to bifunctional compounds, which contain on one end a VHL or cereblon ligand which binds to the E3 ubiquitin ligase and on the other end a moiety which binds tau protein, such that tau protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of tau. The present disclosure exhibits a broad range of pharmacological activities associated with degradation/inhibition of tau protein. Diseases or disorders that result from aggregation or accumulation of tau protein are treated or prevented with compounds and compositions of the present disclosure.
    Type: Grant
    Filed: July 17, 2020
    Date of Patent: February 27, 2024
    Assignee: ARVINAS OPERATIONS, INC.
    Inventors: Andrew P. Crew, Michael Berlin, Angela M. Cacace, Julian T. Chandler
  • Patent number: 11903920
    Abstract: An oil-based formulation comprising a cannabinoid and pico size carbon particles. The formulation is suitable for administration to a patient having a medical condition requiring the use of cannabinoid.
    Type: Grant
    Filed: February 4, 2022
    Date of Patent: February 20, 2024
    Assignee: CHIROSYN DISCOVERY TECHNOLOGIES INC.
    Inventor: Sreedhar Cheekoori
  • Patent number: 11905230
    Abstract: The present invention relates to a novel phenoxyacetic acid derivative represented by the general formula (I), preparation method thereof and use of a pharmaceutical composition containing the derivative in preparing a medicament for treating diabetes and metabolic syndrome. The phenoxyacetic acid derivatives have excellent in vivo hypoglycemic activity, which can be used for preventing or treating diabetes.
    Type: Grant
    Filed: May 24, 2018
    Date of Patent: February 20, 2024
    Assignee: CHINA PHARMACEUTICAL UNIVERSITY
    Inventors: Hai Qian, Wenlong Huang, Chunxia Liu, Jianyong Yang
  • Patent number: 11883394
    Abstract: Processes for providing depot injections of recrystallized aripiprazole lauroxil in which particles of the aripiprazole lauroxil have a surface area of about 0.50 to about 3.3 m2/g; and crystals of aripiprazole lauroxil produced by such processes.
    Type: Grant
    Filed: March 24, 2021
    Date of Patent: January 30, 2024
    Assignee: ALKERMES PHARMA IRELAND LIMITED
    Inventors: Wilfredo Morales, Tarek A. Zeidan, Renato A. Chiarella, Steven G. Wright, Jason M. Perry
  • Patent number: 11878973
    Abstract: The present invention provides a compound, or a pharmaceutically acceptable salt thereof, of formula (I): wherein R1, R2, R3, R4, R5, R26, R27, y, R, M, W, L, V, T, Y, J, K and A are as described herein, therapeutic uses of said compounds, uses of said compounds as research chemicals, a pharmaceutical composition and combinations comprising said compounds, and methods for manufacturing the compounds of the invention.
    Type: Grant
    Filed: May 25, 2022
    Date of Patent: January 23, 2024
    Assignee: NOVARTIS AG
    Inventors: Vincent Bordas, Jvan Brun, Markus Furegati, Jacques Hamon, Jürgen Hans-Hermann Hinrichs, Philipp Holzer, Fatma Limam, Henrik Möbitz, Sandro Nocito, Simone Plattner, Niko Schmiedeberg, Joseph Schoepfer, Ross Sinclair Strang, Frédéric Zecri
  • Patent number: 11878074
    Abstract: Disclosed herein are novel pharmaceutical formulations of a neurokinin-1 (NK-1) receptor antagonist suitable for parenteral administration including intravenous administration. Also included are formulations including both the NK-1 receptor antagonist and dexamethasone sodium phosphate. The pharmaceutical formulations are stable oil-in-water emulsions for non-oral treatment of emesis and are particularly useful for treatment of subjects undergoing highly emetogenic cancer chemotherapy.
    Type: Grant
    Filed: February 19, 2021
    Date of Patent: January 23, 2024
    Assignee: Heron Therapeutics, Inc.
    Inventors: Thomas B. Ottoboni, Han Han
  • Patent number: 11866420
    Abstract: The present invention relates to novel hydrochloride salt forms of N-(2?,4?-difluoro-5-(5-(1-methyl-1H-pyrazol-4-yl)-1H-benzo[d]imidazol-1-yl)-[1,1?-biphenyl]-3-yl)cyclopropanesulfonamide (I). Compound (I) is a selective inhibitor of FGFR/VEGFR kinase families and is useful in the treatment of cancer.
    Type: Grant
    Filed: September 5, 2019
    Date of Patent: January 9, 2024
    Assignee: Aurigene Oncology Limited
    Inventors: David Jonaitis, Oskari Karjalainen
  • Patent number: 11858918
    Abstract: The present disclosure provides GLP-1R agonists, and compositions, methods, and kits thereof. Such compounds are generally useful for treating a GLP-1R mediated disease or condition in a human.
    Type: Grant
    Filed: April 19, 2022
    Date of Patent: January 2, 2024
    Assignee: GILEAD SCIENCES, INC.
    Inventors: Megan K. Armstrong, James S. Cassidy, Elbert Chin, Chienhung Chou, Jeromy J. Cottell, Chao-I Hung, Kavoos Kolahdouzan, David W. Lin, Michael L. Mitchell, Ezra Roberts, Scott D. Schroeder, Nathan D. Shapiro, James G. Taylor, Rhiannon Thomas-Tran, Nathan E. Wright, Zheng-Yu Yang
  • Patent number: 11851424
    Abstract: Forms of (S)-2-hydroxy-6-((4-(2-(2-hydroxyethyl)nicotinoyl)morpholin-3-yl)methoxy)benzaldehyde (Compound I), or salts or solvates thereof, were prepared and characterized in the solid state. Also provided are processes of manufacture and methods of using the forms of Compound I.
    Type: Grant
    Filed: May 13, 2022
    Date of Patent: December 26, 2023
    Assignee: GLOBAL BLOOD THERAPEUTICS, INC.
    Inventors: Stephan D. Parent, Travis Lee Houston, Courtney S. Johnson, Fang Wang
  • Patent number: 11839603
    Abstract: An object of the present invention is to provide an ascorbic acid formulation that can be prepared by a simple method, and that has a reduced unpleasant taste and coloration. The inventors found that an ascorbic acid formulation that is in the form of a water-in-oil type emulsion, that comprises an aqueous phase with a pH of 4 or more and an average particle size of 300 nm or less, and that has a mass ratio of water/ascorbic acid of 0.05 to 0.40 has a reduced unpleasant taste and coloration; and accomplished the present invention. Additionally, the present invention can be prepared by a simple method.
    Type: Grant
    Filed: January 28, 2019
    Date of Patent: December 12, 2023
    Assignee: FUJI OIL HOLDINGS INC.
    Inventors: Arata Hashimoto, Masaharu Kato
  • Patent number: 11840512
    Abstract: Provided is a crystal of a specific oxazole compound that has specific inhibitory activity against PDE4, and that shows excellent stability. Specifically, provided is a crystal of an oxazole compound represented by formula (5) wherein the crystal has peaks at diffraction angles 2?(°) of 9.6±0.2, 19.1±0.2, and 21.2±0.2 in an X-ray powder diffraction pattern measured using CuK? characteristic X-rays.
    Type: Grant
    Filed: July 7, 2022
    Date of Patent: December 12, 2023
    Assignee: OTSUKA PHARMACEUTICAL CO., LTD.
    Inventors: Naohiko Kanai, Takayuki Yasutomi, Ryosuke Hirota
  • Patent number: 11839607
    Abstract: A memantine paroxetine cocrystal salt and its preparation method, pharmaceutical composition and application thereof are provided. The cocrystal salt of the invention is memantine paroxetine sulfate hydrate. Its mechanism of action is 5-HT inhibitor and NMDA receptor antagonist. It is a multi-target drug. The preliminary pharmacokinetic experiments showed that the main pharmacokinetic parameters of cocrystal salt and memantine, such as T1/2, Tmax, Cmax and AUC(0-?), were significantly different. The results also showed that cocrystal salt could improve drug absorption, blood drug concentration, bioavailability and curative effect. This provides a material basis for reducing dosage and adverse drug reactions. In addition to that the cocrystal salt of this invention can be used as a multi-target drug, it can also combine with other drugs of different action mechanisms to form compound preparations or be used in combination, so as to obtain unexpected clinical efficacy.
    Type: Grant
    Filed: February 22, 2019
    Date of Patent: December 12, 2023
    Assignee: HEFEI KEDA BIO-TECHNOLOGY CO. LTD
    Inventors: Ke Wang, Qianliu Cheng, Zonggui Wang, Yan Geng, Xun Zhao
  • Patent number: 11833160
    Abstract: The present invention relates to compounds derived from ursodeoxycholic acid of formula (I), to methods for obtaining same, as well as the use thereof in the treatment of polycystic diseases, particularly autosomal dominant polycystic liver disease, autosomal dominant polycystic kidney disease, or autosomal recessive polycystic kidney disease.
    Type: Grant
    Filed: December 28, 2018
    Date of Patent: December 5, 2023
    Assignees: UNIVERSIDAD DEL PAIS VASCO/EUSKAL HERRIKO UNIBERTSITATEA, ADMINISTRACIO GENERAL DE LA COMUNIDAD AUTONOMA DE EUSKADI, FUNDACIO INSTITUT D'INVESTIGACIO BIOMEDICA DE BELLVITGE (IDIBELL), UNIVERSIDAD DE SALAMANCA
    Inventors: Jesus Maria Banales Asurmendi, Luis Bujanda Fernandez De Pierola, Alvaro Santos Laso, Fernando Pedro Cossio Mora, Ivan Rivilla De La Cruz, Francisco Javier Caballero Camino, Manel Esteller Badosa, Jose Juan Garcia Marin
  • Patent number: 11801246
    Abstract: A method of treating a subject suffering from an ischemic disease associated with Ca2+ overload is provided, the method including administering to the subject an effective amount of an inhibitor of Ataxia telangiectasia and Rad3-related (ATR) kinase. Also provided is a method of treating a subject suffering from acute ischemic stroke, the method including administering to the subject an effective amount of the ATR kinase inhibitor berzosertib.
    Type: Grant
    Filed: November 8, 2019
    Date of Patent: October 31, 2023
    Assignee: EAST TENNESSEE STATE UNIVERSITY RESEARCH FOUNDATIO
    Inventors: Theodoor Hagg, Yue Zou
  • Patent number: 11771702
    Abstract: Disclosed are PPAR receptor modulators and their uses in medicine. The novel agonists for PPAR-? were found by screening molecules through a chemoinformatics-based model. The novel agonists for PPAR-? are proposed for use in medicine.
    Type: Grant
    Filed: November 28, 2019
    Date of Patent: October 3, 2023
    Inventor: Amiram Goldblum
  • Patent number: 11767309
    Abstract: The present disclosure provides methods of synthesizing a compound of Formula (P)-I. The method proceeds through several different pathways including several novel chiral separations, a Sonogashira coupling, a zinc mediated reductive cyanation, as well as through various halide containing intermediates. Also disclosed is the multi-kilogram preparation of several novel intermediates.
    Type: Grant
    Filed: November 23, 2021
    Date of Patent: September 26, 2023
    Assignee: Aclaris Therapeutics, Inc.
    Inventors: Gary A. Decrescenzo, John Robert Springer
  • Patent number: 11766432
    Abstract: Described are conjugates comprising a water-soluble polymer linked to a compound comprising a catechol moiety via a cleavable linkage, wherein the cleavable linkage is formed between the water-soluble polymer and a first phenolic hydroxyl group of the catechol moiety and a second phenolic hydroxyl group of the catechol moiety is linked to a blocking group wherein the rate of hydrolytic release of the compound comprising the catechol moiety is controlled, at least in part, through structure or design of the blocking group on the second phenolic hydroxyl group of the catechol moiety. Therefore, the rate of hydrolytic release of the compound comprising the catechol moiety can be tuned through structural design of the group on the second phenolic hydroxyl group of the catechol moiety. Compounds used in the synthesis of the described conjugates and methods of using the described conjugate and other compounds in the treatment of dopamine-responsive disorders are also described.
    Type: Grant
    Filed: July 27, 2019
    Date of Patent: September 26, 2023
    Assignee: Serina Therapeutics, Inc.
    Inventors: Michael Bentley, Zhihao Fang, Rebecca Weimer, Tacey Viegas, Randall Moreadith